With the FDA emphasis on personalized medicine for patients with orphan diseases, the National Cancer Institute has recently awarded a Neuroendocrine Tumor Specialized Program of Research Excellence to the Holden Comprehensive Cancer Center at the University of Iowa to fund both basic and clinical research on neuroendocrine tumors.
